drugset / Trial / NCT05095636
Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This open, single-center, randomized phase II study was to evaluate the clinical benefit of apatinib plus camrelizumab which is an anti-Programmed cell death-1 (PD-1) monoclonal antibody, versus apatinib in patients with metastatic gastric cancer refractory to two or more lines of treatment, fully evaluating the efficacy and safety of the combined regimen.
Timeline
- Start
- 2021-03-17
- Primary completion
- 2023-03
- Completion
- 2023-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Rivoceranib | Small molecule | 250 mg | Oral |
| Subject | Rivoceranib | Small molecule | 500 mg | Oral |